Klotho Neurosciences (NASDAQ:KLTO) Trading Down 8.8% – What’s Next?

Klotho Neurosciences, Inc. (NASDAQ:KLTO)’s stock price traded down 8.8% during trading on Wednesday . The stock traded as low as $0.45 and last traded at $0.45. 576,864 shares changed hands during trading, a decline of 24% from the average session volume of 763,235 shares. The stock had previously closed at $0.4936.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Klotho Neurosciences in a report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Klotho Neurosciences Price Performance

The company has a fifty day moving average price of $0.52 and a 200 day moving average price of $0.74. The company has a market cap of $32.64 million, a PE ratio of -1.41 and a beta of 10.03.

Klotho Neurosciences (NASDAQ:KLTO) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.05) EPS for the quarter.

Institutional Investors Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC acquired a new position in Klotho Neurosciences, Inc. (NASDAQ:KLTO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences at the end of the most recent quarter. Institutional investors own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.